Overview
- The late-stage DREAMS-3 study enrolled 349 adults with type 2 diabetes and obesity and compared mazdutide 6 mg with injectable semaglutide 1 mg over 32 weeks.
- Mazdutide recipients lost a mean 10.29% of body weight versus 6.0% with semaglutide, and HbA1c declined by 2.03 percentage points versus 1.84.
- The trial met its primary composite endpoint, with 48% on mazdutide achieving HbA1c below 7.0% and at least 10% weight loss at week 32 compared with 21% on semaglutide (p<0.0001).
- Novo Nordisk did not immediately comment on the company-reported findings, and the full dataset has not been peer reviewed.
- Innovent holds China rights to mazdutide through a 2019 deal with Eli Lilly and sells the drug in China for type 2 diabetes, reflecting intensifying competition in the GLP-1 market.